Brox.AI’s Hamish Brocklebank on why it retired “digital twin” for “digital clone” — and why the distinction matters for pharma research accuracy.
Feature|Articles|September 14, 2026
Why Fragmented Contract Processes Are Slowing Pharmaceutical Operations
Author(s)Tom Cowen
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
Advertisement
Advertisement
The pharmaceutical industry has made significant investments in digital transformation, ranging from AI-led drug discovery and clinical trial optimization to advanced analytics and real-world evidence generation. As a result, digital technologies are changing how the industry discovers, commercializes and delivers medicines.
Related to this article
Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Shionogi’s Dr. Draica on why COVID-19 still matters — and why the window between exposure and symptoms is where XOCOVA can intervene.
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Hansoh Pharma enters a collaboration and license agreement with Roche covering a broad portfolio of antibody-drug conjugate programs.
European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.
Advertisement
Advertisement